Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

ICON Public Limited Company

ICLR•NASDAQ
Healthcare
Medical - Diagnostics & Research
$104.66
$4.96(4.97%)
U.S. Market opens in 15h 46m

ICLR News Today: Stay Updated with the Latest ICON Public Limited Company News in Real Time

Find ICLR news now at Meyka AI. Stay informed with the latest ICON Public Limited Company stocks updates, including price news, market analysis, and expert insights.

^GSPC Today: February 23 – DHS PreCheck U-turn, Global Entry Still Paused
📅 in about 5 hours

^GSPC Today: February 23 – DHS PreCheck U-turn, Global Entry Still Paused

DHS reversed plans to suspend TSA PreCheck while Global Entry stays paused amid a partial government shutdown. How this “global entry tsa precheck shut” debate could impact airport flow, airlines, and

Read more
SPYI.DE falls 96% to €10.31 on XETRA (23 Feb 2026): key signals for investors
📅 in about 5 hours

SPYI.DE falls 96% to €10.31 on XETRA (23 Feb 2026): key signals for investors

Market closed: SPYI.DE stock plunged 96% to €10.31 on XETRA on 23 Feb 2026; analysis, technicals and forecasts

Read more
Pre-market volume spike for 43Q.SI stock at S$0.12 on 24 Feb 2026: assess targets
📅 in about 5 hours

Pre-market volume spike for 43Q.SI stock at S$0.12 on 24 Feb 2026: assess targets

Pre-market volume spike in 43Q.SI stock at S$0.12 on 24 Feb 2026. Quick technicals, Meyka AI grade and forecast for SES-listed Advancer Global Limited

Read more
SRN.AX Surefire up 100% pre-market ASX 24 Feb 2026: volume surge
📅 in about 5 hours

SRN.AX Surefire up 100% pre-market ASX 24 Feb 2026: volume surge

SRN.AX stock jumps 100% pre-market on ASX with volume spike; short-term traders driving activity

Read more
February 24: Takaichi Cabinet 2.0 Backs Drug Investment, Biosimilar Parity
📅 in about 5 hours

February 24: Takaichi Cabinet 2.0 Backs Drug Investment, Biosimilar Parity

Takaichi Cabinet 2.0 backs public-private drug R&D and extends Japan drug pricing reform 2026 to biologics via the G1 rule, moving originator prices toward biosimilar parity. What it means for Japan’s

Read more
OCX OncoCyte NASDAQ After Hours 23 Feb 2026: $3.20 oversold bounce, watch $3.80
📅 in about 5 hours

OCX OncoCyte NASDAQ After Hours 23 Feb 2026: $3.20 oversold bounce, watch $3.80

OCX stock rises to $3.20 after hours on 23 Feb 2026 after an oversold bounce; analysis, price targets and risks for NASDAQ-listed OncoCyte

Read more
UBS Downgrades Gerresheimer AG (GRRMF) to Sell on Feb 23, 2026
📅 in about 5 hours

UBS Downgrades Gerresheimer AG (GRRMF) to Sell on Feb 23, 2026

UBS downgrades Gerresheimer; quick take on the Feb 23, 2026 GRRMF analyst rating and investor implications

Read more
Volume spike: BKMINDST.BO BKM Industries Ltd (BSE) pre-market 24 Feb 2026 watch order flow
📅 in about 5 hours

Volume spike: BKMINDST.BO BKM Industries Ltd (BSE) pre-market 24 Feb 2026 watch order flow

Pre-market volume spike in BKMINDST.BO stock on 24 Feb 2026; **volume 123,145** vs avg 180, price INR **1.81**

Read more
PNL.AS PostNL N.V. (EURONEXT) Q4 23 Feb 2026: EBIT up, dividend cut, margin pressure ahead
📅 in about 5 hours

PNL.AS PostNL N.V. (EURONEXT) Q4 23 Feb 2026: EBIT up, dividend cut, margin pressure ahead

PNL.AS stock Q4: normalised EBIT rose to €79.00M, dividend cut to €0.04. Meyka AI forecast and outlook for investors

Read more

ICLR News FAQ